MIRA Pharmaceuticals, Inc.
MIRA
$1.07
$0.172819.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -40.94% | -52.71% | 4.21% | -5.80% | 476.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.24% | -34.13% | 78.39% | 32.01% | 126.79% |
| Operating Income | 20.24% | 34.13% | -78.39% | -32.01% | -126.79% |
| Income Before Tax | 58.54% | 43.03% | -33.58% | -28.10% | -328.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.54% | 43.03% | -33.58% | -28.10% | -328.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.54% | 43.03% | -33.58% | -28.10% | -328.86% |
| EBIT | 20.24% | 34.13% | -78.39% | -32.01% | -126.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.99% | 48.46% | -20.29% | -15.50% | -791.80% |
| Normalized Basic EPS | 62.98% | 48.42% | -20.37% | -15.47% | -793.07% |
| EPS Diluted | 62.99% | 48.46% | -20.29% | -15.50% | -791.80% |
| Normalized Diluted EPS | 62.98% | 48.42% | -20.37% | -15.47% | -793.07% |
| Average Basic Shares Outstanding | 12.04% | 10.50% | 11.03% | 11.03% | -51.96% |
| Average Diluted Shares Outstanding | 12.04% | 10.50% | 11.03% | 11.03% | -51.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |